Speaker Profile
M.D., President, Viome PRO
Biography
Brad Younggren has spent more than two decades at the forefront of healthcare innovation at six separate companies. He leads Viome PRO, the physician facing side of Viome Life Sciences, spanning molecular diagnostics, early cancer detection and clinical intervention delivered through a growing national network of partner clinics. He co-founded Circulate Health, where he has advanced therapeutic plasma exchange (TPE) as a potential intervention for healthy aging through clinical research and expanded outpatient access, and he is a co-author of its peer reviewed trial published in Aging Cell. Earlier he helped build two of digital health's most closely watched companies, 98point6 and Cue Health. A board-certified emergency physician, former U.S. Army combat physician and Bronze Star recipient, his work today focuses on translating emerging longevity science into evidence-based clinical care.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
